Skip to main content
SpringerPlus

Table 7 pCR is related to combination of CYP1B1 and ERCC1 polymorphisms when adjusted on ER status

From: ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors

CYP1B1 (Leu432Val)

ERCC1 (Asn118Asn)

N

pCR

OR

95% CI

P value

n

%a

CC

TT

19

2

10.5

1

Reference

 

CC

CT

22

11

50.0

16.1

(2.3–112)

0.005

CC

CC

6

1

16.7

2.8

(0.16–47)

0.48

CG

TT

15

1

6.7

0.41

(0.03–5.6)

0.51

CG

CT

20

2

10.0

0.77

(0.09–6.8)

0.81

CG

CC

10

2

20.0

2.4

(0.24–25)

0.45

GG

TT

6

1

16.7

0.89

(0.06–13.5)

0.93

GG

CT

8

3

37.5

4.4

(0.46–41)

0.20

GG

CC

7

2

28.6

3.1

(0.28–34)

0.35

ER−

 

42

15

 

1

Reference

 

ER+

 

71

10

 

0.12

(0.03–0.43)

0.001

  1. Significant results are shown in italic.
  2. pCR pathological complete response.
  3. aPercentages of evaluable patients.
Back to article page